XIENCE V Official Site

Abbott is committed to supporting healthcare professionals in the management of CAD. Use these resources to download patient education material and the latest data from XIENCE V SPIRIT family of clinical trials. You can also access information about reimbursement, continuing education, and upcoming conferences.

NEW

SPIRIT IV 1-Year Data

Presented at TCT September 23, 2009, Gregg W. Stone, MD

NEW

SPIRIT III 3-Year Data

Presented at TCT September 21, 2009, Gregg W. Stone, MD

NEW

COMPARE 1-Year Data

Presented at TCT September 23, 2009, Peter Smits, MD

SPIRIT V 1-Year Data

Presented at PCR May 21, 2009, Prof. Eberhard Grube, MD

SPIRIT II 3-Year Data

Presented at ACC March 29, 2009, Prof. Patrick W. Serruys

SPIRIT II&III: Meta-Analysis 2-Year Data

Presented at the Annual Transcatheter Cardiovascular Therapeutics Meeting October 14, 2008, Gregg W. Stone, MD

SPIRIT III 2 Year Data

Presented at PCR May 13, 2008, Gregg W. Stone, MD

SPIRIT II 2 Year Data

Presented at ACC March 31, 2008, Prof. Patrick W. Serruys

SPIRIT II&III: Meta-Analysis 12-month results

Presented at Thoraxcenter, Erasmus Medical Center, October 23, 2007, Prof. Patrick W. Serruys

SPIRIT III: 1-year clinical and angiographic results

Presented at the Annual Transcatheter Cardiovascular Therapeutics Meeting October 22, 2007, Gregg W. Stone, MD

SPIRIT III: 9-month clinical, angiographic, and IVUS results

Presented at the American College of Cardiology, 56th Annual Scientific Session March 24, 2007, Gregg W. Stone, MD

SPIRIT II: 6-month clinical, angiographic, and IVUS results

Presented at the European Society of Cardiology September 5, 2006, Prof. Patrick W. Serruys

Patient Information Guide

Help your patients learn more about CAD and the XIENCE V stent system. The XIENCE V Patient Information Guide illustrates the stent procedure and outlines the risks and benefits of treating with XIENCE V.

Recent Press Releases

FDA Approves Abbott's XIENCE V Drug Eluting Stent

Crossroads Institute

The Crossroads Institute provides a real-world educational experience for healthcare professionals at all stages of their careers.

Additional resources

Euro PCR

Information on the Euro PCR 2008 conference

TCT MD

An educational resource for the interventional cardiology and endovascular medicine community

TheHeart.org

A leading resource for information on treating and preventing cardiovascular disorders

CRT Online

Abstracts, industry news, and educational tools sponsored by the Cardiovascular Research Institute

Solaci

The official Web site for The Latin American Society of Interventional Cardiology

Summit-TCT Asia Pacific

A scientific and international conference focused on interventional vascular therapy.

* In SPIRIT II, XIENCE V demonstrated superiority versus TAXUS stents with a statistically significant 69% reduction in the primary endpoint of in-stent late loss at 6 months (0.11mm vs 0.36mm; P_NI and P_SUP<0.0001). Both TAXUS Express² (73% of lesions) and TAXUS Liberte (27% of lesions) were used as controls in SPIRIT II. Source: P. Serruys et al. EuroIntervention 2006; 2:286-294 & data on file at Abbott Vascular. In SPIRIT III, XIENCE V demonstrated superiority versus TAXUS Express² with a statistically significant 50% reduction in the primary endpoint of in-segment late loss at 8 months (0.14mm vs 0.28mm; P_NI <0.0001, P_SUP=0.004). Source: G. Stone et al. JAMA 2008; 299(16):1903-1913.